TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model
{{output}}
Chimeric antigen receptor (CAR) T cell therapy has demonstrated significant clinical efficacy in patients with hematologic cancers. However, long-term follow-up studies indicate that only 50% of patients remain in complete remission after three years. To overc... ...
